EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Design, synthesis and evaluation of benzofuran-acetamide scaffold as potential anticonvulsant agent

Ashok K Shakya, Mehnaz Kamal, Vishal M Balaramnavar, Sanna K Bardaweel, Rajashri R Naik, Anil K Saxena, H H Siddiqui

Acta Pharmaceutica · 01.09.2016 · 66 (3) · 353-372

DOI: 10.1515/acph-2016-0023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica, online erschienen am 29.06.2016. Verfasst von Ashok K Shakya und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Drug Design, Models, Molecular. Die Arbeit wurde bisher 18-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of N-(2-(benzoyl/4-chlorobenzoyl)-benzofuran- 3-yl)-2-(substituted)-acetamide derivatives (4a-l, 5a-l) was synthesized in good yield. All synthesized compounds were in agreement with elemental and spectral data. The anticonvulsant activity of all synthesized compounds was assessed against the maximal electroshock induced seizures (MES) model in mice. Neurotoxicity was evaluated using the rotarod method. The majority of compounds exhibited anticonvulsant activity at a dose of 30 mg kg-1 body mass during 0.5-4 h, indicating their ability to prevent seizure spread at low doses. Relative to phenytoin, [N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(cyclohexyl( methyl) amino)-acetamide] (5i) and [N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(4-methylpiperidin-1- yl)-acetamide] (5c) demonstrated comparable relative anticonvulsant potency of 0.74 and 0.72, respectively, whereas [(N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(4-(furan-2-carbonyl)-piperazin-1-yl)-acetamide] (5f) exhibited the lowest relative potency of 0.16. The ALD50 of tested compounds ranged from 1.604 to 1.675 mmol kg -1 body mass. The ED50 of synthesized compounds ranged from 0.055 to 0.259 mmol kg -1 (~23.4 to 127.6 mg kg -1 ) body mass. The pharmacophore mapping of the examined compounds on standard drugs (phenobarbital, phenytoin, ralitolin and carbamazepine) strongly suggests that these compounds may exert their anticonvulsant activity via the same established mechanism as that of known drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignModels, Molecular4-Aminobutyrate TransaminaseAcetamidesAnimalsAnticonvulsantsBenzofuransBinding SitesCerebellumDose-Response Relationship, DrugGABA AgonistsGlycineLethal Dose 50MaleMedulla OblongataMesencephalonMiceMolecular Docking SimulationNeuronsNeurotoxicity SyndromesRats, WistarSeizures

Substanzen

AcetamidesAnticonvulsantsBenzofuransGABA AgonistsN-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(4-methylpiperidin-1-yl)acetamideN-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(cyclohexyl(methyl)amino)acetamidegamma-Aminobutyric Acid4-Aminobutyrate TransaminaseGlycine

Zitieren

APA

Shakya, A. K., Kamal, M., Balaramnavar, V. M., Bardaweel, S. K., Naik, R. R., Saxena, A. K., & Siddiqui, H. H. (2016). Design, synthesis and evaluation of benzofuran-acetamide scaffold as potential anticonvulsant agent. Acta Pharmaceutica, 66(3), 353-372. https://doi.org/10.1515/acph-2016-0023

Vancouver

Shakya AK, Kamal M, Balaramnavar VM, Bardaweel SK, Naik RR, Saxena AK, et al. Design, synthesis and evaluation of benzofuran-acetamide scaffold as potential anticonvulsant agent. Acta Pharmaceutica. 2016;66(3):353-372. doi:10.1515/acph-2016-0023

BibTeX
@article{Shakya2016,
  author = {Shakya, Ashok K and Kamal, Mehnaz and Balaramnavar, Vishal M and Bardaweel, Sanna K and Naik, Rajashri R and Saxena, Anil K and Siddiqui, H H},
  title = {Design, synthesis and evaluation of benzofuran-acetamide scaffold as potential anticonvulsant agent},
  journal = {Acta Pharmaceutica},
  year = {2016},
  volume = {66},
  number = {3},
  pages = {353--372},
  doi = {10.1515/acph-2016-0023}
}
Kostenlos starten →